From Risk Categories to Risk-Adapted Care: Comparing the 2025 American Thyroid Association and 2024 Korean Thyroid Association Risk Stratification Systems in Differentiated Thyroid Cancer Authors: Won Gu Kim, Mijin Kim Published: 2026 In differentiated thyroid cancer (DTC) management, initial risk stratification is a fundamental component that provides the basis for decisions regarding adjuvant therapy and follow-up intensity. The 2025 American Thyroid Association (ATA) and 2024 Korean Thyroid Association (KTA) guidelines employ recurrence risk-based stratification systems at the time of diagnosis. Although the overall framework is comparable, there exists a key structural difference: the ATA guideline adopts a four-tier system (low, low-intermediate, intermediate-high, and high risks) [1], whereas the KTA guideline maintains a three-tier system (low, intermediate, and high risks) [2,3]. This modification by the ATA may be interpreted as an effort to further refine the heterogeneous intermediate-risk group, which had been associated with a broad range of recurrence risk in previous guidelines [1,4]. These differences should not be interpreted merely as differences in classification structure, because initial risk categories may influence subsequent decisions regarding adjuvant radioactive iodine therapy, thyroid-stimulating hormone suppression, and postoperative surveillance intensity. Because many clinicians may not have the opportunity to compare both guidelines in detail, Table 1 provides a side-by-side summary of the major category-defining differences between the 2024 KTA and 2025 ATA risk stratification systems. Several clinically relevant differences are observed in the assignment of patients to specific risk categories. First, there are differences in the definition of low-risk disease (Table 1). In the ATA guideline, the inclusion of cases with only microscopic involvement at the anterior margin (R1 resection) is not clearly supported by sufficient evidence, and such cases are not explicitly incorporated into the low-risk category [1]. In contrast, the KTA guideline allows certain patients with multifocal tumors to be classified as low risk when other low-risk criteria are met, reflecting evidence suggesting that multifocality alone may not significantly increase the recurrence risk [2,3]. Furthermore, there are differences in the interpretation of microscopic extrathyroidal extension (ETE). In the ATA guideline, microscopic ETE is regarded as an independent risk factor and generally assigned to the low-intermediate risk category [1]. However, the KTA guideline allows cases with microscopic ETE alone to be classified as low-risk disease when all other features meet low-risk criteria and no additional adverse factors are present [2,3]. Consequently, the KTA framework may include a broader subset of patients within the low-risk category under carefully defined conditions. This broader low-risk definition should not be interpreted as a less stringent approach, but rather as an effort to avoid automatic upstaging based on isolated microscopic ETE or multifocality when other adverse clinicopathologic features are absent. Table 1Comparison of Initial Risk Stratification Categories in the 2024 KTA and 2025 ATA Guidelines2024 KTA2025 ATALow-risk groupEstimated risk of recurrence 5% or lessaEstimated risk of recurrence 10% or less All criteria must be metNo local or distant metastasisNo distant metastasisR0 resectionR0 or only microscopic & anterior Margin (R1)PTC, non-aggressive subtypePTC, non-aggressive subtypeFTC/OCA/I-EFVPTC, minimally invasiveFTC/OCA/I-EFVPTC, minimally invasive≤2 cm (pT1a) PTC≤4 cm (pT1–2)2–4 cm (pT1b) BRAFWT, PTC≤4 cm (pT1–2) FTC, I-EFVPTC, OTCUnifocal or multifocalUnifocalNo ETE or microscopic ETEbNo extrathyroidal extensionNo vascular invasionNo vascular invasioncN0 or N1 (≤5 LNs, all ≤2 mm)cN0 or N1a (≤5 LNs, all ≤2 mm)If RAI Tx, no uptake outside the thyroid bedHigh-risk groupEstimated risk of recurrence ≥30%aEstimated risk of recurrence >30% Any criteriaAny of the followings;pT3a+microscopic extrathyroidal extensionGross extrathyroidal extension (pT4), excluding pT3b (limited to strap muscle involvement)pT3b or pT4or any of the followingsPDTC, DHGTCPDTC, DHGTCFTC/OCA/I-EFVPTC, widely invasiveFTC/OCA/I-EFVPTC, widely invasiveExtensive vascular invasion ≥4 fociFTC/OCA/I-EFVPTC, vascular invasion ≥4 fociGross incomplete resection (R2)Gross incomplete resection (R2)Cervical LN metastasis >3 cmcN1 ≥3 cm or extranodal extensionDistant metastasisDistant metastasis2 or more high-risk mutations (TERT promoter+BRAFV600E or RAS mutationsIntermediate-risk groupEstimated risk of recurrence >5% and ≤30%aNot categorized as either a low-risk or high-risk groupLow-intermediate risk groupEstimated risk of recurrence 10%–15%T3a, T1, or T2 with any of the followingUnilateral multifocality, PTCLimited vascular invasion <4 foci, FTC/OCA/I-EFVPTCMicroscopic ETEcN1a or pN1a >2 mm or >5 LNsNegative margins or microscopic+posterior margin (R1)High-intermediate risk groupEstimated risk of recurrence ≥16%–30%T3a, T1, or T2 with any of the followingClinical lateral LN metastasis (cN1b) <3 cm2+Low-intermediate risk factorsBilateral mutifocality >1 cm, PTCAggressive histology, PTCVascular invasion, PTCThis table summarizes the major category-defining differences between the two guidelines and is not intended to reproduce all guideline recommendations. KTA, Korean Thyroid Association; ATA, American Thyroid Association; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; OCA, oncocytic carcinoma of thyroid; I-EFVPTC, invasive encapsulated follicular variant of papillary thyroid carcinoma; ETE, extrathyroidal extension; LN, lymph node; RAI, radioactive iodine; Tx, treatment; PDTC, poorly differentiated thyroid carcinoma; DHGTC, differentiated high-grade thyroid carcinoma.aThe recurrence risk estimates in the 2024 KTA guideline refer to estimated 10-year recurrence rates;bIn the KTA guideline, microscopic ETE alone, when all other features meet low-risk criteria and no additional adverse factors are present, to be classified as the low-risk category. Endocrinol Metab 2026 Forthcoming. Posted online 2026 Comparison of Initial Risk Stratification Categories in the 2024 KTA and 2025 ATA Guidelines This table summarizes the major category-defining differences between the two guidelines and is not intended to reproduce all guideline recommendations. KTA, Korean Thyroid Association; ATA, American Thyroid Association; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; OCA, oncocytic carcinoma of thyroid; I-EFVPTC, invasive encapsulated follicular variant of papillary thyroid carcinoma; ETE, extrathyroidal extension; LN, lymph node; RAI, radioactive iodine; Tx, treatment; PDTC, poorly differentiated thyroid carcinoma; DHGTC, differentiated high-grade thyroid carcinoma. The recurrence risk estimates in the 2024 KTA guideline refer to estimated 10-year recurrence rates; In the KTA guideline, microscopic ETE alone, when all other features meet low-risk criteria and no additional adverse factors are present, to be classified as the low-risk category. Endocrinol Metab 2026 Forthcoming. Posted online 2026 Second, differences are more pronounced in the definition of high-risk disease, particularly with respect to gross ETE. In the KTA guideline, high-risk classification is largely limited to tumors with gross ETE corresponding to pT4a disease [2,3]. By contrast, the ATA guideline includes not only gross ETE extension but also selected cases within the T3 category (including T3a and T3b) in the high-risk group [1]. This approach may lead to an expansion of the high-risk population. Whether all of these T3 subsets consistently reach the recurrence-risk threshold associated with high-risk disease remains uncertain, and further validation would be helpful. Third, there are also discrepancies the role of lymph node (LN) metastasis in defining high-risk disease. In the ATA guideline, clinical LN metastasis (cN1) with a size of ≥3 cm is included as a criterion for high-risk classification [1]. By contrast, the KTA guideline places greater emphasis on pathological LN characteristics, particularly the size of metastatic LNs identified on histopathologic examination [2,3]. Although extranodal extension (ENE) is recognized as a factor associated with increased recurrence risk, whether it can independently justify classification into the high-risk group after adjusting for other LN-related features remains unclear. Additional studies are needed to clarify the independent prognostic impact of ENE in this context. These differences highlight an unresolved issue in nodal risk assessment: whether individual nodal features, such as ENE or clinically measured LN size, are sufficient to define high-risk disease, or whether nodal risk should be interpreted as a composite burden incorporating the number, size, location, and ENE of metastatic LNs. Finally, compared with the 2015 ATA guideline, wherein the intermediate-risk category encompassed a broad range of recurrence risk (~5% to 30%) [1,4], the 2025 ATA guideline subdivides this group into low-intermediate and intermediate-high categories [1]. This modification appears to reflect an effort to better delineate the heterogeneous intermediate-risk population. However, there is limited evidence supporting a more granular separation of intermediate-risk patients into narrower recurrence risk ranges, despite relatively well-defined boundaries for low-and high-risk disease. Moreover, the clinical validity of this subdivision requires further validation. By contrast, the KTA guideline retains a single intermediate-risk category and explicitly characterizes it as a heterogeneous group wherein recurrence risk varies according to the number and combination of adverse clinicopathologic features [2,3]. The KTA framework emphasizes the cumulative effect of coexisting intermediate-risk factors in refining risk estimation, rather than introducing additional subcategories. Nevertheless, stratifying patients into four distinct categories may offer the advantage of facilitating more individualized treatment strategies. Further studies providing robust evidence are needed to validate this approach and enhance the precision of risk stratification in DTC. Taken together, although the 2025 ATA and 2024 KTA guidelines share a broadly similar framework for initial risk stratification, there are important differences in how specific clinicopathologic features are assigned to risk categories. These differences are most evident at the boundaries of low- and high-risk definitions and in the structural handling of the intermediate-risk group. Consequently, the size and composition of each risk category may vary depending on the guideline applied, which could influence subsequent decisions regarding adjuvant therapy and follow-up strategies. Although the ATA guideline adopts a more structured approach through the expansion of risk categories, the KTA guideline emphasizes interpretive flexibility within a stable framework. These complementary approaches highlight the ongoing challenge of balancing simplicity, accuracy, and clinical applicability in risk stratification. Further refinement of risk stratification systems, supported by robust prospective evidence, will be essential to improve consistency in risk classification and optimize the individualized management of patients with DTC. Ultimately, the value of a risk stratification system lies not only in its ability to classify patients accurately, but also in its capacity to guide risk-adapted treatment and surveillance while minimizing unnecessary intervention. Footnotes CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported. REFERENCES